Mashima, T., Iwasaki, R., Kawata, N., Kawakami, R., Kumagai, K., Migita, T., Sano, T., Yamaguchi, K. and Seimiya, H. In silico chemical screening identifies epidermal growth factor receptor as a therapeutic target of drug-tolerant CD44v9-positive gastric cancer cells.
Br. J. Cancer., in press (2019) |
Udagawa, C., Horinouchi, H., Shiraishi, K., Kohno, T., Okusaka, T., Ueno, H., Tamura, K., Ohe, Y. and Zembutsu, H. Whole genome sequencing to identify predictive markers for the risk of drug-induced interstitial lung disease.
PLoS One, in press (2019) |
Hara-Nakano, M., Udagawa, C., Shimo, A., Kojima, Y., Yoshie, R., Zaha, H., Abe, N., Tokiwa, M., Uensoko, M., Tamura, K., Shimoi , T., Yoshida, M., Yoshida, T., Sakamoto, H., Kato, K., Mushiroda, T., Tsugawa, K. and Zembutsu, H. A genome-wide association study identifies five novel genetic markers for trastuzumab-induced cardiotoxicity in Japanese population.
Biol. Pharm. Bull., in press (2019) |
Katayama, R., Gong, B., Togashi, N., Miyamoto, M., Kiga, M., Iwasaki, S., Kamai, Y., Tominaga, Y., Takeda, Y., Kagoshima, Y., Shimizu, Y., Seto, Y., Oh-hara, T., Koike, S., Nakao, N., Hanazawa, H., Watanabe, K., Yoda, S., Yanagitani, N., Hata, A. N., Shaw, A. T., Nishio, M., Fujita, N. and Isoyama, T. The new-generation selective ROS1/NTRK Inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models
Nat. Commun., in press (2019)
ニュースリリース文章はこちら
|
Suzuki, Y., Kobayashi, K., Wakisaka, Y., Deng, D., Tanaka, S., Huang, C. J., Lei, C., Liu, H., Fujiwaki, Y., lee, S., isozaki, A., Kasai, Y., hayakawa, T., Sakuma, S., Arai, F., Koizumi, K., Tezuka, H., Inaba, M., hiraki, K., Ito, T., Hase, M., Matsusaka, S., Shiba, K., Suga, K., Nishikawa, M., Jona, M., Yatomi, Y., Yaxiaer, Y., Tanaka, Y., Sugimura, T., Nitta, N., Goda, K. and Yasuyuki, O. Label-free chemical imaging flow cytometry by high-speed multicolor stimulated Raman scattering.
Proc. Natl. Acad. Sci. U. S. A., in press (2019) |
Okada, K., Araki, M., Sakashita, T., Ma, B., Kanada, R., Yanagitani, N., Horiike, A., Koike, S., Oh-Hara, T., Watanabe, K., Tamai, K., Maemondo, M., Nishio, M., Ishikawa, T., Okuno, Y., Fujita, N. and Katayama, R. Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance.
EBioMedicine, 41, 105-119 (2019) |
Gong, B., Kiyotani, K., Sakata, S., Nagano, S., Kumehara, S., Baba, S., Besse, B., Yanagitani, N., Friboulet, L., Nishio, M., Takeuchi, K., Kawamoto, H., Fujita, N. and Katayama, R. Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancer.
J. Exp. Med., 216, 982-1000 (2019) |
Suenaga, M., Wakatsuki, T., Mashima, T., Ogura, M., Ichimura, T., Shinozaki, E., nakayama, I., Osumi, H., Ota, Y., Takahari, D., Chin, K., Seimiya, H. and yamaguchi, K. A phase I study to determine the maximum tolerated dose of trifluridine/tipiracil and oxaliplatin in patients with refractory metastatic colorectal cancer: LUPIN study.
Invest. New Drugs., in press (2019) |
Matsumura, S., Minamisawa, T., Suga, K., Kishita, H., Akagi, T., Ichiki, T., Ichikawa, Y. and Shiba, K. Subtypes of tumour cell-derived small extracellular vesicles having differently externalized phosphatidylserine.
J. Extracell. Vesicles, 8, (2019) |
Osumi, H., Shinozaki, E., Yamaguchi, K. and Zembutsu, H. Clinical utility of circulating tumor DNA for colorectal cancer.
Cancer Sci., in press (2019) |
